Bridging the Transparency Gap: Trump Administration Overhauls Health Insurance Disclosure Rules on October 6, 2026 Posted by
Legal Showdown: Federal Appeals Court Skeptical of HHS in High-Stakes Medicare Advantage Audit Battle on October 6, 2026 Posted by
GE HealthCare Bolsters Radiopharmaceutical Dominance with Strategic Acquisition of Sofie Biosciences on October 6, 2026 Posted by
Unpacking the Disparities: How Maternal Health and Ethnicity Intersect in Autism Risk on October 6, 2026 Posted by
Shionogi Scales Up Rare Disease Ambitions with $2 Billion IntraBio Acquisition on October 5, 2026 Posted by
Celebrating Excellence: Honoring the Vital Contributions of Respiratory Therapists in Our Communities on October 5, 2026 Posted by
Bridging the Transparency Gap: Trump Administration Overhauls Health Insurance Disclosure Rules on October 6, 2026 Posted by
Legal Showdown: Federal Appeals Court Skeptical of HHS in High-Stakes Medicare Advantage Audit Battle on October 6, 2026 Posted by
GE HealthCare Bolsters Radiopharmaceutical Dominance with Strategic Acquisition of Sofie Biosciences on October 6, 2026 Posted by
Unpacking the Disparities: How Maternal Health and Ethnicity Intersect in Autism Risk on October 6, 2026 Posted by
Posted in Medical Innovations A Legacy of Transformation: Andy Plump to Depart Takeda Following Decade of R&D Reimagining on September 11, 2026
Posted in Medical Innovations Takeda’s Mimrylo Approval Marks a Paradigm Shift in Polycythemia Vera Treatment on August 31, 2026
Posted in Sleep Health Breakthrough in Narcolepsy Treatment: Analyzing the Clinical and Economic Impact of Takeda’s Oveporexton on August 23, 2026
Posted in Medical Innovations A New Dawn for Narcolepsy: Takeda’s Orzeyful Signals a Paradigm Shift in Sleep Medicine on August 6, 2026
Posted in Sleep Health Breakthrough in Narcolepsy Treatment: Takeda’s Oveporexton Shows Promise in Phase 3 Clinical Trials on July 6, 2026
Posted in Sleep Health A New Dawn for Narcolepsy: Takeda’s Oveporexton Shows Transformative Potential in Phase 3 Trials on June 24, 2026
Posted in Sleep Health Beyond Symptom Management: Takeda’s Oveporexton Shows Promise in Redefining Narcolepsy Type 1 Treatment on June 16, 2026
Posted in Medical Innovations Takeda’s Zasocitinib Challenges the TYK2 Status Quo: A New Horizon for Oral Psoriasis Treatment on June 15, 2026
Posted in Digital Health Tools The $2.6 Billion Verdict: How a ‘Pay-for-Delay’ Settlement Landed Takeda in Antitrust Crosshairs on May 23, 2026 rifanmuazin
Posted in Medical Innovations Takeda Pharmaceuticals Agrees to $13.6 Million Settlement Over Kickback Allegations Involving Trintellix on May 15, 2026 rifanmuazin
